About Us We are an interdisciplinary team focused on providing breakthrough immunotherapies for cancer patients Read More
FUSIX Technology We are working on an immunotherapeutic approach based on a fusogenic oncolytic virus Read More
Investment We are looking for investors following our pre-seed funding for a planned university spin-out in 2022 Read More
FUSIX platform We are finalizing the preclinical data package and pharm/tox studies according to regulatory standards with a focus on liver and pancreatic cancer as first clinical indications.
Combination Therapies We are developing the FUSIX technology as a platform for immunotherapeutic combination approaches. Immunotherapies have shown their most efficient treatment effects in combination.
Portfolio We are continuously working on the development of next generation viruses containing therapeutic transgenes that are optimized for immunotherapeutic efficiency and combination therapy.